Drug Approval | December 12, 2023
Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Decision on EU marketing authorisation expected for momelotinib by early 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Subscribe To Our Newsletter & Stay Updated
